~~<i id='5F2CE8F9D6'><strike id='5F2CE8F9D6'><tt id='5F2CE8F9D6'><pre id='5F2CE8F9D6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

leisure time

author：hotspot 2025-08-25 15:10:06 - browse：5398

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： AstraZeneca loses challenge to Medicare drug price negotiation

explore

entertainment

knowledge

leisure time

knowledge

CommitteeRankingRepublicanBillCassidy(La.)andChairmanBernieSanders(I-Vt.)ChipSomodevilla/GettyImages

WSS

Obesity now affects over 1 billion people worldwide, study finds

Pfizer highlights cancer drugs it thinks could reignite investor interest

How to fix the rural physician shortage in the U.S.

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

FDA does about

Flu vaccine offering decent levels of protection this winter, new data show

knowledge

leisure time

explore

Virginia high school admissions case could be legal follow

Scientists unlock the key to scar

Cancer drug shortages should be causing more outrage

Clinical trials giant ICON acquires HumanFirst

As demand for Covid shots wanes, Moderna seeks its next success

International team creates first chimeric human

New air purifier tech could be key to improving indoor air quality

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

The cancer drug shortage isn’t new — and neither are the solutions

Scientists unlock the key to scar

entertainment

Senate panel passes drug pricing bills, but drops one PBM reform

Pfizer highlights cancer drugs it thinks could reignite investor interest

House looks to weaken Medicare negotiation

Biotech companies concerned about China biosecurity crackdown

Timeline: Key moments in fight for gay rights

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

knowledge

leisure time

leisure time

knowledge